We are building the future of Alzheimer's Disease detection

Synaps DX

Pioneering Precision in Alzheimer’s Diagnostics

Founded on the belief that early and accurate diagnosis can transform the trajectory of Alzheimer's disease, SYNAPS Dx was born from a convergence of scientific innovation and heartfelt mission. Driven by personal experiences with the devastating impacts of Alzheimer’s, our founders, a team of renowned neurologists and pathologists, set out to revolutionize how Alzheimer's is detected and managed.

Our journey began in the research lab of Rockville, Maryland, where our dedicated scientists embarked on a decade-long quest to develop a diagnostic solution that could overcome the limitations of existing methods. The result was DISCERN™, the world’s only Gold Standard validated skin biopsy test that distinguishes Alzheimer's disease from other forms of dementia with unprecedented precision.

OUR values
Our Commitment to Values and Patient-Centric Innovation
Patient-Centric CareEvery test and every decision at SYNAPS Dx prioritizes the patient. We treat each sample with the utmost respect and diligence, understanding the profound impact our work has on individuals and their families.
Integrity in Every ActionIntegrity is the cornerstone of all our interactions. From transparent communication with healthcare providers to ethical dealings in every aspect of our operations, we ensure that our actions consistently reflect our dedication to honesty and moral responsibility.
Innovative ExcellenceInnovation drives us to transcend traditional boundaries in Alzheimer's diagnostics. Our teams are empowered to explore new ideas and solutions, enhancing our ability to deliver diagnostic services that set industry standards.
Ethical ResponsibilityWe are committed to lessening both the economic and emotional impacts of Alzheimer's disease. Our focus is on providing cost-effective, reliable diagnostic solutions that not only support patients but also contribute to broader societal benefits.
Paul Tanico
Executive Chairman
Michael Gibbons
Director
Peter Lucey
Director
Kyle Mowitz
Director
Daniel Alkon, MD
Chief Scientific Advisor
Norelle Wildburger, PhD
COO
Curt Pattee
CFO
Tom Alexander, PhD
CLIA Lab Director
Alberto J. Espay, MD, MSc, FAAN, FANA
Giulio Taglialatela, PhD
Donna Wilcock, PhD
Lon Schneider, MD, MS
David Morgan, PhD
Michael Gorton
Dave Rosa
Fred Huie
Management Team
Daniel Alkon, MD
Chief Scientific Advisor
Norelle Wildburger, PhD
COO
Curt Pattee
CFO
Tom Alexander, PhD
CLIA Lab Director

Board of Directors

Scientific Advisory Board
Alberto J. Espay, MD, MSc, FAAN, FANA
Giulio Taglialatela, PhD
Donna Wilcock, PhD
Lon Schneider, MD, MS
David Morgan, PhD
Advisory Council
Michael Gorton
Dave Rosa
Fred Huie
OUR LOCATION

The Lab

We operate a state of the art facility located at 12441 Parklawn Dr., Suite 2A, Rockville, MD 20852, where the we employ former BRNI scientists who conducted the research.

The SYNAPS Dx lab is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. SYNAPS Dx is the exclusive licensee of the worldwide patent portfolio covering the biomarker technology.

Learn More about discern™
Explore the Future of Alzheimer’s Diagnostics
Learn more about DISCERN™ on our dedicated website. See how our precision diagnostics are changing lives and advancing care.
Visit the DISCERN™ Website